Scholar Rock Holding (SRRK) | Financial Analysis & Statements
Scholar Rock Holding Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-91.9M
Net Income
-91.0M
Balance Sheet Metrics
Total Assets
404.3M
Total Liabilities
158.8M
Shareholders Equity
245.5M
Debt to Equity
0.65
Cash Flow Metrics
Operating Cash Flow
-67.3M
Free Cash Flow
-75.5M
Revenue & Profitability Trend
Scholar Rock Holding Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 33.2M | 18.8M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 208.4M | 184.6M | 121.9M | 124.4M | 108.5M |
| Selling, General & Administrative | 176.2M | 67.5M | 49.4M | 43.1M | 40.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 384.6M | 252.1M | 171.3M | 167.6M | 148.7M |
| Operating Income | -384.6M | -252.1M | -171.3M | -134.4M | -129.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -404.8% | -690.5% |
| Non-Operating Items | |||||
| Interest Income | 13.9M | - | - | - | - |
| Interest Expense | 6.9M | - | - | - | - |
| Other Non-Operating Income | -301.0K | 5.8M | 5.5M | -132.0K | -1.9M |
| Pre-tax Income | -377.9M | -246.3M | -165.8M | -134.5M | -131.8M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -377.9M | -246.3M | -165.8M | -134.5M | -131.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | -405.2% | -700.5% |
| Key Metrics | |||||
| EBITDA | -369.4M | -250.1M | -168.5M | -131.4M | -127.3M |
| EPS (Basic) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 |
| EPS (Diluted) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 |
| Basic Shares Outstanding | 114701154 | 99838102 | 83347086 | 59611656 | 36711833 |
| Diluted Shares Outstanding | 114701154 | 99838102 | 83347086 | 59611656 | 36711833 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Scholar Rock Holding Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 323.5M | 177.9M | 101.9M | 103.3M | 212.8M |
| Short-term Investments | 44.0M | 259.4M | 178.1M | 212.1M | 40.2M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | 12.7M | 12.3M |
| Total Current Assets | 385.1M | 451.2M | 288.2M | 328.0M | 265.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 21.0M | 25.9M | 21.7M | 28.8M | 34.9M |
| Goodwill | - | 2.4M | - | - | - |
| Intangible Assets | - | 2.4M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.8M | 2.4M | 6.8M | 4.2M | 4.1M |
| Total Non-Current Assets | 19.1M | 23.8M | 22.8M | 30.1M | 39.1M |
| Total Assets | 404.3M | 474.9M | 311.0M | 358.2M | 304.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.3M | 10.1M | 3.5M | 4.0M | 4.4M |
| Short-term Debt | 5.6M | 5.8M | 8.7M | 7.9M | 9.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 85.0K | 222.0K | 230.0K |
| Total Current Liabilities | 55.4M | 46.9M | 32.7M | 36.4M | 64.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 103.4M | 59.4M | 53.1M | 61.5M | 68.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 103.4M | 59.4M | 53.1M | 61.5M | 68.1M |
| Total Liabilities | 158.8M | 106.3M | 85.8M | 97.9M | 132.4M |
| Equity | |||||
| Common Stock | 108.0K | 94.0K | 76.0K | 52.0K | 35.0K |
| Retained Earnings | -1.3B | -922.7M | -676.4M | -510.6M | -376.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 245.5M | 368.6M | 225.2M | 260.2M | 172.1M |
| Key Metrics | |||||
| Total Debt | 108.9M | 65.1M | 61.8M | 69.4M | 77.1M |
| Working Capital | 329.7M | 404.2M | 255.5M | 291.6M | 201.0M |
Balance Sheet Composition
Scholar Rock Holding Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -377.9M | -246.3M | -165.8M | -134.5M | -131.8M |
| Depreciation & Amortization | 1.7M | 1.9M | 2.8M | 3.0M | 2.6M |
| Stock-Based Compensation | 75.6M | 36.6M | 27.1M | 27.7M | 23.1M |
| Working Capital Changes | -5.9M | 1.7M | -11.2M | -41.0M | -23.6M |
| Operating Cash Flow | -300.8M | -200.5M | -139.6M | -137.2M | -122.9M |
| Investing Activities | |||||
| Capital Expenditures | -602.0K | -98.0K | -58.0K | -1.1M | -5.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -98.0M | -293.2M | -290.8M | -300.6M | -60.4M |
| Investment Sales | 317.3M | 217.2M | 332.0M | 130.0M | 200.0M |
| Investing Cash Flow | 218.7M | -76.1M | 41.1M | -171.7M | 134.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 74.7M | - | - | 0 | 25.0M |
| Debt Repayment | -25.5M | - | 0 | -975.0K | 0 |
| Financing Cash Flow | 140.8M | 324.3M | 97.7M | 193.4M | 38.1M |
| Free Cash Flow | -300.6M | -201.0M | -145.3M | -133.8M | -132.0M |
| Net Change in Cash | 58.6M | 47.7M | -767.0K | -115.5M | 49.5M |
Cash Flow Trend
Scholar Rock Holding Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-14.43
Forward P/E
-22.09
Price to Book
20.98
PEG Ratio
-22.09
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-123.08%
Return on Assets
-54.69%
Financial Health
Current Ratio
6.95
Debt to Equity
44.37
Beta
0.69
Per Share Data
EPS (TTM)
$-3.29
Book Value per Share
$2.26
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SRRK | 5.5B | -14.43 | 20.98 | -123.08% | 0.00% | 44.37 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






